Relugolix (Orgovyx®). HTA ID: 23017

Assessment Status Rapid Review Complete
HTA ID 23017
Drug Relugolix
Brand Orgovyx®
Indication Indicated for the treatment of adult patients with advanced hormone-sensitive prostate cancer.
Assessment Process
Rapid review commissioned 14/03/2023
Rapid review completed 31/03/2023
Rapid review outcome A full HTA is not recommended. The NCPE recommends that relugolix not be considered for reimbursement at the submitted price*.

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.